{
    "nctId": "NCT03495609",
    "briefTitle": "Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers",
    "officialTitle": "The Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers",
    "overallStatus": "COMPLETED",
    "conditions": "hCG, BRCA1 Mutation, BRCA2 Mutation",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Does Ovitrelle result in early prevention of breast cancer in BRCA1 and BRCA2 carriers?",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* premenopausal women\n* BRCA1 carrier\n\nExclusion Criteria:\n\n* History of allergic reaction to compounds of similar chemical or biologic composition to hCG\n* receiving medication that could interfere with the study protocol objectives (hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin)\n* previous treatment with follicle stimulating hormone for assisted reproduction\n* uncontrolled intercurrent illness\n* Heart disease\n* Severe cognitive decline\n* Psychiatric desease\n* HIV positive\n* Hepatitis B or C infection",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}